Document Type
Article - Restricted
Publication Date
2017
Abstract
BACKGROUND: Several novel drugs have been approved by the US Food and Drug Administration (FDA) in the past 5 years for the treatment of patients with non–small-cell lung cancer (NSCLC). Despite new treatments, lung cancer remains a major cause of cancer-related death in the United States.
OBJECTIVE: To review the treatment of patients with advanced NSCLC, with a focus on drugs that were recently approved by the FDA for this patient population.
DISCUSSION: Platinum-based regimens remain the first-line treatment for patients with advanced NSCLC that is not associated with driver mutations. The recent drugs approved by the FDA in the past 5 years for NSCLC include afatinib, alectinib, ceritinib, crizotinib, erlotinib, gefitinib, necitumumab, nivolumab, osimertinib, pembrolizumab, and ramucirumab. Several of these agents have been found to increase overall survival in the first- and second-line settings. These medications also have different toxicity profiles compared with the traditional cytotoxic drugs used in the treatment of NSCLC. This article highlights the outcomes associated with these novel therapies in the treatment of patients with NSCLC.
CONCLUSION: The novel therapies introduced into the market in the past 5 years have significantly improved outcomes for patients with advanced NSCLC.
Recommended Citation
Ignoffo, R. J., Lindfelt, T., & Lozano, E. (2017). Novel systemic therapies for advanced non–small-cell lung cancer. Journal Of Hematology Oncology Pharmacy, 7(1), 34-43.
Publisher's Statement
Originally published in Journal Of Hematology Oncology Pharmacy, 7(1), 34-43. Reprinted with the permission of the publisher. Access on Touro Scholar restricted to Touro-affiliated users only. The original material can be found here.
